Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501769 · ClinicalTrials.gov registry record · Phase 1
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
A Phase 1 study, sponsored by Arvinas Estrogen Receptor.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05501769: Completed Phase 1 study, sponsored by Arvinas Estrogen Receptor.
NCT05501769 is a Phase 1 study that has completed, run by Arvinas Estrogen Receptor. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501769, a Phase 1 study, has completed, sponsored by Arvinas Estrogen Receptor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
Interventions
- DRUG ARV-471 in combination with Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2025-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05501769
The ClinicalTrials.gov registry entry for NCT05501769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arvinas Estrogen Receptor, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARV-471 in combination with Everolimus is the first listed.
NCT05501769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05501769 about?
NCT05501769 is a clinical study titled "ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer". A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
What is the current status of trial NCT05501769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-09-08. Estimated completion is 2025-08-25.
What interventions are being tested in trial NCT05501769?
The interventions under investigation include: ARV-471 in combination with Everolimus (DRUG).
Who is sponsoring clinical trial NCT05501769?
This trial is sponsored by Arvinas Estrogen Receptor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.